Visit UC San Diego's Coronavirus portal for the latest information for the campus community.
Children's Oncology Group (COG) is a National Cancer Institute (NCI) supported clinical trials group, is the world's largest organization devoted exclusively to childhood and adolescent cancer research. The COG unites more than 9,000 experts in childhood cancer at more than 200 leading children's hospitals, universities, and cancer centers across North America, Australia, New Zealand, and Europe in the fight against childhood cancer.
Today, more than 90% of 14,000 children and adolescents diagnosed with cancer each year in the United States are cared for at Children's Oncology Group member institutions. COG's unparalleled collaborative efforts provide the information and support needed to answer important clinical questions in the fight against cancer.
The Children's Oncology Group has nearly 100 active clinical trials open at any given time. These trials include front-line treatment for many types of childhood cancers, studies aimed at determining the underlying biology of these diseases, and trials involving new and emerging treatments, supportive care, and survivorship.
The Children's Oncology Group research has turned children's cancer from a virtually incurable disease 50 years ago to one with a combined 5-year survival rate of 80% today. Our goal is to cure all children and adolescents with cancer, reduce the short and long-term complications of cancer treatments, and determine the causes and find ways to prevent childhood cancer.
UCSD/RCHSD PI: William Roberts, MD
Beat Childhood Cancer Research Consortium , formerly known as Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC), is a group of 40+ universities and children's hospitals that offer a worldwide network of childhood cancer clinical. These trials are based on the research from a group of closely collaborating investigators who are linked with laboratory programs developing novel therapies for high-risk pediatric cancers. Our mission is to continue to use precision medicine to bring forward new therapies for children with cancer with the goal of finding a cure for these patients.
North American Pediatric Aplastic Anemia Consortium (NAPAAC) is a collaborative research effort that seeks to develop better therapies for children with aplastic anemia by combining the expertise and resources of the leading pediatric hematologists in North America.
UCSD/RCHSD PI: Nicholas Gloude, MD
Pacific Pediatric Neuro-Oncology Consortium (PNOC) is a network of eight children's hospitals that conduct clinical trials of new therapies for children with brain tumors. Our goal is to improve outcomes by translating the latest findings in cancer biology into better treatments for these children. At PNOC, our focus is personalized medicine – testing new therapies that are specific to the biology of each patient's tumor to maximize their effectiveness. Our goal is to improve overall outcome for children with brain tumors.
UCSD/RCHSD PI: John Crawford, MD, MS
Pediatric Blood and Marrow Transplant Consortium (PBMTC) is the largest clinical trials group focused exclusively on blood and marrow transplants for children and adolescents. Our consortium includes more than 100 pediatric BMT centers in the United States, Canada, New Zealand, and Australia. PBMTC is a core member of the NIH-funded Blood and Marrow Transplant (BMT) Clinical Trials Network (CTN) and has a close collaborative relationship with the Children's Oncology Group (COG). The PBMTC has clinical trials activities focused on the application of BMT for younger patients and works in concert with many of our industrial partners. As the largest forum focused on pediatric BMT, the PBMTC is committed to research that improves clinical outcomes of BMT in children and adolescents. By vigorously advocating for our patients and their families, we strive to increase awareness and resources for all of those who must undergo this life saving treatment.
UCSD/RCHSD PI: Eric Anderson, MD
This unique alliance is designed to benefit both patient care and research efforts. It enables St. Jude, Rady Children's , and UCSD to combine their resources and expertise to pursue clinical trials and basic and translational research.
UCSD/RCHSD PIs: Deborah Schiff, MD
Pediatric Immune Deficiency Treatment Consortium (PIDTC) consists of 42 centers in North America whose shared goal is to improve the outcome of patients with rare, life threatening, inherited disorders of the immune system. Basic scientists, immunologists, and transplant physicians from the participating centers have contributed much of the current knowledge of the cause and treatments of PID. The immediate focus of the consortium is to concentrate on three severe immune disorders which can be cured by hematopoietic stem cell transplantation, enzyme replacement, and/or or gene therapy by bringing together physician/scientists who evaluate and care for the majority of children with PID in North America.